02-19-2017  8:50 am      •     

E. Albert Reece, M.D., Ph.D.

 

May 18, 2011, was HIV Vaccine Awareness Day, a time to remind ourselves of the worldwide effort to create vaccines to help prevent HIV infection and to boost the immune systems of people already infected with the virus.  

The past three weeks have seen a flurry of activity around new and exciting potential HIV-vaccine concepts.

In Kenya, clinical trials began on two promising new designs for preventive HIV vaccines.  In South Africa, researchers launched clinical trials on a therapeutic vaccine intended to strengthen the immune systems of people living with HIV/AIDS.  And just last week, scientists at the University of Maryland School of Medicine announced their biggest research gift ever: $23.4 million to continue the university's decades-long work on an HIV/AIDS vaccine from a consortium led by the Bill & Melinda Gates Foundation.

"I don't think anyone can argue that this has been an exciting time," says Mitchell Warren, executive director of AVAC, originally the AIDS Vaccine Advocacy Coalition, the 16-year-old New York City-based group that advocates for the development of an AIDS vaccine and biomedical prevention.

Prevention technologies have been in the news lately--from the breakthrough microbicide research at the 2010 International AIDS Conference to the recent data on the potential of pre-exposure prophylaxis (PrEP) to help protect gay and bisexual men.  And, all have potentially serious implications for African Americans, who represent only 13 percent of the U.S. population but account for 45 percent of new HIV infections.

Preventive Vaccine Trials

"There are three major areas of work right now around vaccines," Warren explains.  "On the one hand, there is a lot of work focused on doing better than what we did in Thailand, how to modify that vaccine candidate and improve upon it."

Announced in September 2009, the U.S.-funded "Thai Prime-Boost" trial--the world's largest, with 16,000 volunteers--combined two previously unsuccessful vaccines.  But, while a medical milestone (the vaccine reduced new infections by almost a third), it was not effective enough.

"The second major area of work is other new vaccine concepts. The trial in Kenya is one example," says Warren of the research being conducted in collaboration with the (IAVI).  The candidate vaccine affects both antibodies and cellular immune response and has been described as the most advanced AIDS vaccine design" likely to succeed.

Novel HIV-Vaccine Candidate?

Another major effort includes the early research dollars that the National Institutes of Health and the Gates Foundation are providing to the University of Maryland for entirely new vaccine concepts based on other scientific ideas.

The funding was awarded to the university's Institute of Human Virology, headed by the renowned Robert C. Gallo, M.D., who helped discover the human immunodeficiency virus that causes AIDS and later developed the HIV blood test.  If effective, the novel HIV-vaccine candidate would neutralize many different strains of HIV."   Previous vaccine candidates responded only to a single type of the disease.

"With the possibility of an HIV vaccine that could prevent many different strains of this disease, we could indeed be changing the world," says E. Albert Reece, M.D., Ph.D., M.B.A., dean of the University of Maryland School of Medicine.  Dr. Reece, who is African American, describes the new vaccine candidate's potential as "extraordinary."

New Proteins

The third major focus of research "has gotten a lot of people excited," says AVAC's Warren.  "That's been the discovery of more than a dozen new neutralizing antibodies.  For almost 30 years of the epidemic, there were only a few known antibodies. . . . Scientists broke the code and [can] find additional areas of the HIV virus that might be better targets."  Neutralizing antibodies defend cells from an infection by working to inhibit, or "neutralize," the pathogen's effect.

One recent example: Scientists in Oregon recently announced an experimental vaccine that helped monkeys with a form of HIV control their infections for more than a year.  This is the first time that a vaccine candidate has been able to "fully control the virus in some animals," Wayne C. Koff, Ph.D., chief scientific officer at the IAVI, told Reuters.

Some Progress on Therapeutic Vaccines

Positive developments have also occurred on therapeutic vaccines, intended to one day boost the ravaged immune systems of people living with HIV/AIDS.

Clinical trials on a vaccine candidate called TAT were announced at the University of Limpopo in South Africa.  Participants continue to take their antiretroviral medications (ARVs) as researchers investigate "what health restorative qualities the candidate vaccine has that ARVs do not possess," reports The Sowetan.

This approach appears particularly promising for African and Caribbean nations, where many patients do not have easy access to lifesaving ARVs.  An estimated 5.7 million HIV-positive people live in South Africa alone--more than in any other nation.

But, the stateside HIV/AIDS-treatment-and-research community is divided on the benefits of funding therapeutic strategies because many people are on ARV therapy, which is largely effective.  Stephen Bailous, vice president of community affairs at the National Association of People With AIDS</a>, defends the approach.   "We need to have hopes, and some of the therapeutic vaccines look really promising," Bailous is quoted by Scientific American.

Recruiting Blacks for Vaccine Trials

"In the long term, the preventive vaccine is the goal standard," says Ben Perkins, associate director of community education at the Boston-based Fenway Institute.

"It's great that the PrEP study has shown that uninfected men who have sex with men can take medication and decrease their likelihood of HIV acquisition," he says.  "But, that is medication you have to take on a daily basis under medical supervision.  A vaccine is just a couple of shots; maybe later you get a booster. That's it."

In addition to doing community outreach and working with AIDS-service organizations around the country, "my job is also to talk about HIV-vaccine research and try to get people of color involved in trials," Perkins says.  A participant in the STEP-study phase 2 clinical vaccine trials, Perkins recently uploaded a video to YouTube discussing the importance of Black involvement.

"My childhood best friend died from AIDS-related complications in 1991 at 27 years old," Perkins says. "In addition, once I later came out as a gay man, my first partner had an AIDS diagnosis.  It's impacted me personally, and it's important to do my part to help find a vaccine. . . . We were able to eradicate smallpox through vaccine several generations ago.  I'd like to see the same thing happen with HIV."

Blacks and Latinos are generally underrepresented in clinical research.  There has been a nationwide, sustained effort by the NIH-funded HIV Vaccine Trials Network's Legacy Project to recruit more Black and Latino participants.  "In the United States, African Americans are at greatest risk for HIV.  Not to acknowledge that, or not to design our research around that, means we are reinforcing the very obstacles that the virus preys upon," AVAC's Warren reminds us.  "Whether it be for a vaccine, for a therapy, microbicide or PrEP, we need to make sure that diverse populations are enrolling in the clinical trials.

"But we will find a vaccine," Warren adds.  "There is no doubt, given all the recent advances."

Rod McCullom, a writer and television news producer, blogs on Black gay, lesbian, bisexual and transgender news and pop culture at rod20.com.

Recently Published by The Skanner News

  • Default
  • Title
  • Date
  • Random
  • WASHINGTON (AP) — One month after the inauguration, the stretch of Pennsylvania Avenue in front of Donald Trump's White House still is a hard-hat zone. Skeletal remains of the inaugural reviewing stands poke skyward. Random piles of plywood and cables are heaped on the ground inside crooked lines of metal fencing. The disarray outside the president's front door, though not his fault, serves as a metaphor for the tumult still unfolding inside. Four weeks in, the man who says he inherited "a mess" at home and abroad is presiding over a White House that is widely described as itself being a mess. At a stunning pace, Trump has riled world leaders and frustrated allies. He was dealt a bruising legal blow on one of his signature policies. He lost his national security adviser and his pick for labor secretary to scandal. He's seen forces within his government push back against his policies and leak confidential information. All of this has played out amid a steady drip of revelations about an FBI investigation into his campaign's contacts with Russian intelligence officials. Trump says his administration is running like a "fine-tuned machine." He points to the rising stock market and the devotion of his still-loyal supporters as evidence that all is well, although his job approval rating is much lower than that for prior presidents in their first weeks in office. Stung by the unrelenting criticism coming his way, Trump dismisses much of it as "fake news" delivered by "the enemy of the people" — aka the press. Daily denunciations of the media are just one of the new White House fixtures Americans are adjusting to. Most days start (and end) with presidential tweets riffing off of whatever's on TV talk shows or teasing coming events or hurling insults at the media. At some point in the day, count on Trump to cast back to the marvels of his upset of Democrat Hillary Clinton in the November election and quite possibly overstate his margins of support. Expect more denunciations of the "dishonest" press and its "fake news." From there, things can veer in unexpected directions as Trump offers up policy pronouncements or offhand remarks that leave even White House aides struggling to interpret them. The long-standing U.S. policy of seeking a two-state solution to the Israeli-Palestinian conflict? Trump this past week offered this cryptic pronouncement: "I'm looking at two-state and one-state, and I like the one that both parties like. I can live with either one." His U.N. ambassador, Nikki Haley, the next day insisted, "We absolutely support a two-state solution." Trump's days are busy. Outside groups troop in for "listening sessions." Foreign leaders call or come to visit. (Or, in the case of Mexico's president, cancel out in pique over Trump's talk about the planned border wall.) After the president signed two dozen executive actions, the White House was awaiting a rush order of more of the gold-plated Cross pens that Trump prefers to the chrome-plated ones used by his predecessor. Trump hands them out as souvenirs at the signing ceremonies that he points to as evidence of his ambitious pace. "This last month has represented an unprecedented degree of action on behalf of the great citizens of our country," Trump said at a Thursday news conference. "Again, I say it. There has never been a presidency that's done so much in such a short period of time." That's all music to the ears of his followers, who sent him to Washington to upend the established order and play the role of disrupter. "I can't believe there's actually a politician doing what he says he would do," says an approving Scott Hiltgen, a 66-year-old office furniture sales broker from River Falls, Wisconsin. "That never happens." Disrupt Trump has. But there may be more sound and fury than substance to many of his early actions. Trump did select Judge Neil Gorsuch to replace the late Antonin Scalia on the Supreme Court, a nomination that has drawn strong reviews from conservatives. But the president is regrouping on immigration after federal judges blocked his order to suspend the United States' refugee program and ban visitors from seven Muslim-majority countries, which had caused chaos for travelers around the globe. Some other orders on issues such as the U.S.-Mexico border wall and former President Barack Obama's health care law are of limited effect. Trump says his early actions show he means to deliver on the promises he made during the campaign. "A lot of people say, 'Oh, oh, Trump was only kidding with the wall,'" the president told a group of police chiefs recently. "I wasn't kidding. I don't kid." But the Republican-led Congress is still waiting to see specifics on how Trump wants to proceed legislatively on top initiatives such as replacing the health care law, enacting tax cuts and revising trade deals. The messy rollout of the travel ban and tumult over the ouster of national security adviser Michael Flynn for misrepresenting his contacts with Russia are part of a broader state of disarray as different figures in Trump's White House jockey for power and leaks reveal internal discord in the machinations of the presidency. "I thought by now you'd at least hear the outlines of domestic legislation like tax cuts," says Princeton historian Julian Zelizer. "But a lot of that has slowed. Trump shouldn't mistake the fact that some of his supporters like his style with the fact that a lot of Republicans just want the policies he promised them. He has to deliver that." Put Senate Majority Leader Mitch McConnell, R-Ky., in the camp of those more interested in substance than style. "I'm not a great fan of daily tweets," McConnell said Friday, referring to the "extra discussion" that Trump likes to engage in. But McConnell was quick to add: "What I am a fan of is what he's been actually doing." He credits Trump with assembling a conservative Cabinet and taking steps to reduce government regulation, and promised: "We like his positions and we're going to pursue them as vigorously as we can." The challenge may be to tease out exactly what Trump wants in the way of a health care plan, tax changes and trade policy. At his long and defiant news conference on Thursday, Trump tried to dispel the impression of a White House in crisis, squarely blaming the press for keeping him from moving forward more decisively on his agenda. Pointing to his chief of staff, Reince Priebus, Trump said, "You take a look at Reince, he's working so hard just putting out fires that are fake fires. I mean, they're fake. They're not true. And isn't that a shame because he'd rather be working on health care, he'd rather be working on tax reform." For all the frustrations of his early days as president, Trump still seems tickled by the trappings of his office. When New Jersey Gov. Chris Christie visited the White House last week to discuss the national opioid epidemic over lunch, the governor said Trump informed him: "Chris, you and I are going to have the meatloaf.'" Trump added: "I'm telling you, the meatloaf is fabulous." ___Follow Nancy Benac on Twitter at http://twitter.com/nbenac
    Read More
  • FDR executive order sent 120,000 Japanese immigrants and citizens into camps
    Read More
  • Pruitt's nomination was strongly opposed by environmental groups and hundreds of former EPA employees
    Read More
load morehold SHIFT key to load allload all